We are live on ! Find out more
XENT

Intersect ENT, Inc

Delisted

XENT was delisted on the 12th of May, 2022.

112 hedge funds and large institutions have $521M invested in Intersect ENT, Inc in 2019 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 44 increasing their positions, 33 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

430% more call options, than puts

Call options by funds: $16.1M | Put options by funds: $3.05M

200% more funds holding in top 10

Funds holding in top 10: 13 (+2)

33% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 33

0% more funds holding

Funds holding: 112112 (0)

0% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 20

25% less capital invested

Capital invested by funds: $690M → $521M (-$169M)

Holders
112
Holders Change
Holders Change %
0%
% of All Funds
2.46%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.07%
New
20
Increased
44
Reduced
33
Closed
20
Calls
$16.1M
Puts
$3.05M
Net Calls
+$13.1M
Net Calls Change
+$2.12M

XENT Hedge Fund Activity: Q3 2019 in Review

112 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Intersect ENT, Inc (XENT) for Q3 2019, worth a combined $521M — down 25% from $690M a quarter earlier.

Fund positioning in XENT was balanced in Q3 2019: 20 funds opened new positions, 20 closed out, 44 added to existing stakes and 33 trimmed.

The largest buyer was UBS Group, adding an estimated $25.3M. The largest seller was Invesco, cutting an estimated $31.5M.

  • 112 institutional investors held Intersect ENT, Inc (XENT) as of Q3 2019, unchanged from Q2 2019.
  • Funds reported $521M of Intersect ENT, Inc stock for Q3 2019, down 25% quarter-over-quarter.
  • 20 funds opened new Intersect ENT, Inc positions in Q3 2019 and 20 closed out, a net change of 0 holders.
  • The largest Intersect ENT, Inc buyer in Q3 2019 was UBS Group, an estimated $25.3M added.
  • The largest Intersect ENT, Inc seller in Q3 2019 was Invesco, an estimated $31.5M sold.

Based on aggregated 13F filings for Q3 2019.